Company profile

BrainRepair UG

VZP0676 | Nordrhein-Westfalen

We are using stem cells from own cord blood to treat brain damage in ~30,000 children in need per year (EU) that have been granted Orphan Drug Designation by EC_EMA(EU/3/16/1744). The enormous potential of the treatment was shown in ~400 children worldwide. Our treatment of brain damage in newborn infants is ready for clinical use and will enjoy EU monopoly for 12 years. So far we invested 4.5m €.

Business Model


Customer Focus


European Medicinal Agency EMA

2015: EMA Advanced Therapy Medicinal Product Classification (ATMP-TEP) for autologous mononuclear cells derived from human cord blood

- for the treatment of Paediatric brain damage, Hypoxic-ischaemic encephalopathy, and Cerebral palsy

2016: EMA worldwide first two Orphan Medicinal Product Designations for autologous mononuclear cells derived from human cord blood

- for the treatment of Periventricular leukomalacia (brain damage in preterm newborns)

- for the treatment of Neonatal Encephalopathy (brain damage in term newborns)

2017: EC/EMA 'Seal of Excellence' of the European Commission/EMA for Horizon 2020 proposal and business plan 'STOP-CP!'

2018: Capital increase by two investors (Family Office, Germany; US Entrepreneur, Founder, and Scientist from Georgetown University, Washington D.C.) who invested 1 million Euro Private Equity for 1% of BrainRepair UG shares

2018: BrainRepair UG welcomes a new strategic partner:

1. Genepath Laboratories, Sydney, Australia – Next generation sequencing. Accreditations: NATA, RCPA

2019: BrainRepair UG announces eligibility for INVEST support measure:
1. Eligibility certified by Ministry of Economy and Energy!
2. 20% subsidisation of venture capital by INVEST support measure

Registered Office

Universitätsstr. 140
44799 Bochum


+49 234 588196-0
Send mail